Abstract: The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the FAS receptor (expressed by the FAS gene), thereby decreasing expression of FAS mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of FAS expression and function, such as autoimmune hepatitis.

Abstract: The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).

Abstract: Aspects of the disclosure relate to compositions and methods for modulating levels, function, and/or activity one or more RNA transcripts (e.g., mRNA transcripts) or the proteins in a cell or subject. The disclosure is based, in part, on chemically modified inhibitory nucleic acids that are capable of target RNA knockdown with high specificity and low off-target effects.

Abstract: Provided herein are PLIN1 RNAi agents and compositions comprising a PLIN1 RNAi agent. Also provided herein are methods of using the PLIN1 RNAi agents or compositions comprising a PLIN1 RNAi agent for reducing PLIN1 expression, and/or treating PLIN1 associated metabolic disorder in a subject.

Abstract: The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder.

Abstract: Provided herein are MAPT antisense oligonucleotides and compositions comprising a MAPT antisense oligonucleotide. Also provided herein are methods of using the MAPT antisense oligonucleotides or compositions comprising a MAPT antisense oligonucleotide for reducing MAPT expression and/or treating tauopathy in a subject.

Abstract: Provided herein are SARM1 RNAi agents and compositions comprising a SARM1 RNAi agent. Also provided herein are methods of using the SARM1 RNAi agents or compositions comprising a SARM1 RNAi agent for reducing SARM1 expression, reducing axon degeneration, and/or treating SARM1-mediated neurological disease in a subject.

Abstract: Provided herein are APP RNAi agents and compositions comprising an APP RNAi agent. Also provided herein are methods of using the APP RNAi agents or compositions comprising an APP RNAi agent in reducing APP expression and/or treating APP associated neurological diseases.

Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.

Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.

Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.

Abstract: The present disclosure relates to novel RNAi agents designed to decrease the expression of ANGPTL8 in the liver, where the RNAi agents comprise delivery moieties conjugated to oligonucleotides optionally via a linker. The RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression.

Abstract: An LED bulb includes an LED photoelectric module having at least two branches of LED beads with different color temperatures connected in parallel, a control switch connected with one of the branches of LED beads, and an adjustment ring. A total voltage of one branch of LED beads is less than that of each of the other branches of LED beads. The control switch has a ball, the adjustment ring has a magnet, and when the adjustment ring rotates, the magnet draws the ball to roll to switch on or off the control switch. When the control switch is on, the branch of LED beads connected with the control switch is lighted up, and when the control switch is off, the branch of LED beads connected with the control switch is not lighted up.

Abstract: An LED bulb includes an LED photoelectric module having at least two branches of LED beads with different color temperatures connected in parallel, a control switch connected with one of the branches of LED beads, and an adjustment ring. A total voltage of one branch of LED beads is less than that of each of the other branches of LED beads. The control switch has a ball, the adjustment ring has a magnet, and when the adjustment ring rotates, the magnet draws the ball to roll to switch on or off the control switch. When the control switch is on, the branch of LED beads connected with the control switch is lighted up, and when the control switch is off, the branch of LED beads connected with the control switch is not lighted up.